Grifols (GIFLF) Net Cash Flow (2010 - 2025)
Grifols' (GIFLF) quarterly Net Cash Flow came in at -$1.3 billion in Q4 2025, up 11.19% on a YoY basis from -$1.2 billion in Q4 2024, and up 11.19% quarter-over-quarter from -$1.5 billion in Q4 2024.
Analysis
Grifols (GIFLF) Net Cash Flow (2010 - 2025) Analysis & Trends
Grifols (GIFLF) has reported Net Cash Flow for 15 consecutive years, with -$1.3 billion the latest figure, recorded in Q4 2025.
- For the quarter ending Q4 2025, Net Cash Flow rose 11.19% year-over-year to -$1.3 billion; the trailing twelve-month figure through Dec 2025 stood at -$5.4 billion (down 27.52% YoY), and the FY2025 full-year result was -$68.9 million, down 115.03% from the prior year.
- Net Cash Flow improved to -$1.3 billion in Q4 2025 per GIFLF's latest filing, from -$1.5 billion in the prior quarter.
- Across five years, Net Cash Flow topped out at -$423.9 million in Q4 2023 and bottomed at -$2.2 billion in Q4 2022.
- Historically, Net Cash Flow has averaged -$1.3 billion across 4 years, with a median of -$1.4 billion in 2024.
- The sharpest annual moves came in 2023 and 2024: Net Cash Flow jumped 80.79% in 2023, then plunged 242.57% in 2024.
- Over 4 years, Net Cash Flow stood at -$2.2 billion in 2022, then surged by 80.79% to -$423.9 million in 2023, then slumped by 242.57% to -$1.5 billion in 2024, then grew by 11.19% to -$1.3 billion in 2025.
- According to Business Quant data, Net Cash Flow over the past three periods registered -$1.3 billion, -$1.5 billion, and -$423.9 million for Q4 2025, Q4 2024, and Q4 2023 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 203.97 Bn | 189.99 Bn | 7.24 Bn | 1.95 Bn |
| 2 | Gilead Sciences | 178.74 Bn | 175.56 Bn | 6.22 Bn | -4.43 Bn |
| 3 | Vertex Pharmaceuticals | 130.73 Bn | 122.88 Bn | 2.84 Bn | 652.90 Mn |
| 4 | Regeneron Pharmaceuticals | 80.42 Bn | 72.42 Bn | 3.93 Bn | -504.30 Mn |
| 5 | Argenx Se | 60.40 Bn | 55.21 Bn | 1.37 Bn | - |
| 6 | Moderna | 57.65 Bn | 52.52 Bn | 52.00 Mn | -183.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.37 Bn | 30.07 Bn | 992.69 Mn | -496,000.00 |
| 8 | Biogen | 32.15 Bn | 30.86 Bn | 1.96 Bn | -2.09 Bn |
| 9 | Roivant Sciences | 29.58 Bn | 29.58 Bn | 1.16 Mn | -170.75 Mn |
| 10 | Grifols | 7.54 Bn | 9.09 Bn | 3.33 Bn | -1.29 Bn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | -1.29 Bn |
| Dec 31, 2024 | -1.45 Bn |
| Dec 31, 2023 | -423.92 Mn |
| Dec 31, 2022 | -2.21 Bn |
| Mar 31, 2020 | -130.24 Mn |
| Dec 31, 2019 | -324.92 Mn |
| Mar 31, 2019 | -541.80 Mn |
| Dec 31, 2018 | 1.31 Bn |
| Jun 30, 2018 | -530.10 Mn |
| Mar 31, 2018 | 249.20 Mn |
| Dec 31, 2017 | 4.86 Bn |
| Jun 30, 2017 | 247.39 Mn |
| Mar 31, 2017 | 3.80 Bn |
| Dec 31, 2016 | -72.03 Mn |
| Sep 30, 2016 | -604.20 Mn |
| Dec 31, 2015 | -1.29 Bn |
| Sep 30, 2015 | 271.26 Mn |
| Jun 30, 2015 | 1.43 Bn |
| Mar 31, 2015 | -461.73 Mn |
| Dec 31, 2014 | 389.16 Mn |